Physician profile
Miguel C Risco
NPI 1942445812
$1,747.63
in general payments reported to CMS, 2019-2025
14 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2021: $14.61 · 2022: $90.07 · 2023: $487 · 2024: $370 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.40 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $321.37 | 2023-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $240.47 | 2019-2025 | Tagrisso, Enhertu |
| Genentech USA, INC. | $190.97 | 2021-2025 | Tecentriq |
| Janssen Biotech, INC. | $174.64 | 2019 | |
| Merck Sharp & Dohme LLC | $118.39 | 2023-2024 | Keytruda |
| Emd Serono, INC. | $113.33 | 2019 | |
| Daiichi Sankyo INC. | $111.07 | 2024-2025 | Enhertu, Datroway |
| Pfizer INC. | $110.89 | 2023-2025 | |
| Abbvie INC. | $94.23 | 2025 | |
| Genzyme Corporation | $92.98 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $86.94 | 2023-2025 | Opdivo |
| Myriad Genetic Laboratories, INC. | $34.47 | 2024 | Myrisk |
| Immunogen, INC. | $29.95 | 2023 | Elahere |
| Array Biopharma INC | $27.93 | 2025 | Lorbrena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Risco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.